Sort   by:  
 Page size 
TranscriptomicsImpact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia
We found previously that the effect of decitabine (DAC) on hematopoietic stem cell viability differed between Mll5 wildtype and null cells. We therefore investigated the role of MLL5 expression levels on outcome of AML patients who were treated with decitabine. High MLL5 expressing AML patients have...
ORGANISM(S): Mus musculus 
2014-07-01 | E-GEOD-52199 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human osteosarcoma derived cell lines treated with decitabine
Background: Epigenetic modifications such as methylation silencing of genes with CpG-island-associated promoters is frequently observed in cancer. Studies regarding the implications of epigenetic modifications in osteosarcoma (OS) have been limited. The epigenetic drug decitabine is a potential r...
ORGANISM(S): Homo sapiens 
2008-06-15 | E-GEOD-7454 | biostudies-arrayexpress
GenomicsDirect but No Transgenerational Effects of Decitabine and Vorinostat on Male Fertility
Epigenetic drugs actively altering the epigenome of tumours have been developed for use in anti-cancer therapies. However, these drugs could potentially also affect the DNA methylome of spermatozoa that seems to be essential for male fertility. Here, we analysed possible direct and transgenerational...
ORGANISM(S): Mus musculus 
2015-03-03 | E-GEOD-59575 | biostudies-arrayexpress
Proteomics,MultiomicsHLA peptides (LC-MSMS) induced by Decitabine in Glioblastoma cell lines
Treatment of cancer cells with anti-cancer drugs often fails to achieve complete remission. Yet, such drug treatments may induce alteration in the tumor’s gene expression patterns, including those of Cancer/Testis Antigens (CTA). The degradation products of such antigens can be presented as HLA pept...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2017-03-31 | MSV000080843 | MassIVE
TranscriptomicsExpression profile of PBMCs following decitabine treatment
The epigenetic regulation, for example, DNA methylation, controls the development and differentiation of both tumor cells and immunocytes. Treatment with DNA demethylating agent (such as decitabine) has shown a dramatic clinical benefit in hematological malignancies and solid tumors. However, the in...
ORGANISM(S): Homo sapiens 
2016-06-30 | E-GEOD-72686 | biostudies-arrayexpress
GenomicsSpecific molecular signatures underlie response to decitabine in CMML [ERRBS]
Myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML) are characterized by mutations in epigenetic modifiers and aberrant DNA methylation. DNA methyltransferase inhibitors (DMTis) are used to treat these disorders, but response is highly variable with few means to predict which patien...
ORGANISM(S): Homo sapiens 
2015-03-31 | E-GEOD-61161 | biostudies-arrayexpress
TranscriptomicsSpecific molecular signatures underlie response to decitabine in CMML [RNA-seq]
Myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML) are characterized by mutations in epigenetic modifiers and aberrant DNA methylation. DNA methyltransferase inhibitors (DMTis) are used to treat these disorders, but response is highly variable with few means to predict which patien...
ORGANISM(S): Homo sapiens 
2015-03-31 | E-GEOD-61162 | biostudies-arrayexpress
TranscriptomicsDecitabine-induced DNA methylation-mediated transcriptomic reprogramming in human breast cancer cell lines
Decitabine (DAC), a DNA methyltransferase (DNMT) inhibitor, is tested in combination with conventional anticancer drugs as a treatment option for various solid tumors.
ORGANISM(S): Homo sapiens 
2022-10-20 | E-MTAB-12225 | biostudies-arrayexpress
TranscriptomicsDecitabine-induced DNA methylation-mediated transcriptomic reprogramming in human breast cancer cell lines
JIMT-1 and T-47D cell lines, were transfected with a DCK expression vector and exposed to low-dose decitabine (DAC). DAC, a DNA methyltransferase (DNMT) inhibitor, is tested in combination with conventional anticancer drugs as a treatment option for various solid tumors.
ORGANISM(S): Homo sapiens 
2022-10-20 | E-MTAB-12224 | biostudies-arrayexpress
TranscriptomicsGene expression profiling in primary AML cells treated with decitabine and cytarabine
Acute myeloid leukemia (AML), and other myeloid malignancies, are frequently treated with hypomethylating agents like decitabine. Alterations in the epigenome, induced by decitabine, are likely to result in gene expression changes. The effects of decitabine have not been systemically studied using p...
ORGANISM(S): Homo sapiens 
2012-12-18 | E-GEOD-40442 | biostudies-arrayexpress
Sort   by:  
 Page size